Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Gains from Investment Securities (2021 - 2024)

Trinity Biotech's Gains from Investment Securities history spans 4 years, with the latest figure at $7.0 million for Q4 2024.

  • On a quarterly basis, Gains from Investment Securities rose 169.41% to $7.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $12.5 million, a 145.63% increase, with the full-year FY2024 number at $2.5 million, up 874.71% from a year prior.
  • Gains from Investment Securities hit $7.0 million in Q4 2024 for Trinity Biotech, up from $2.6 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for TRIB hit a ceiling of $7.0 million in Q4 2024 and a floor of -$398000.0 in Q3 2022.
  • Historically, Gains from Investment Securities has averaged $2.1 million across 4 years, with a median of $1.3 million in 2022.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 37.57% in 2022 and later surged 169.41% in 2024.
  • Tracing TRIB's Gains from Investment Securities over 4 years: stood at $4.9 million in 2021, then tumbled by 37.57% to $3.1 million in 2022, then fell by 15.0% to $2.6 million in 2023, then surged by 169.41% to $7.0 million in 2024.
  • Business Quant data shows Gains from Investment Securities for TRIB at $7.0 million in Q4 2024, $2.6 million in Q4 2023, and -$178000.0 in Q3 2023.